Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis

Biological Chemistry

Volumn 379, Issue 8-9, 1998, Pages 987-1006

  Pavone, Vincenzo ^a   De Simone, Giuseppina ^a   Nastri, Flavia ^a   Galdiero, Stefania ^a   Staiano, Norma ^b   Lombardi, Angela ^a   Pedone, Carlo ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antithrombotics; Hirunorms; Thrombin; Thrombin synthetic inhibitors; X ray crystal structure

Indexed keywords

ANTICOAGULANT AGENT; HIRUDIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBIN INHIBITOR;

CHEMICAL STRUCTURE; COMPARATIVE STUDY; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTITHROMBINS; BINDING SITES; HIRUDINS; HUMANS; MOLECULAR MIMICRY; PROTEIN BINDING; PROTEIN CONFORMATION; THROMBIN;

EID: 0031664267     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Abola, E.E., Sussman, J.L, Prilusky, J., and Manning, N.O. (1997). Protein data bank archives of three-dimensional macromolecular structures. Methods Enzymol. 277, 556-571.
2. Ascenzi, P., Amiconi, G., Bode, W., Bolognesi, M., Coletta, M., and Menegatti, E. (1995). Proteinase inhibitors from the European Medicinal Leech Hirudo Medicinalis: structural functional and biomedical aspects. Molec. Aspects. Med. 16, 215-313.
3. Bajusz, S., Barbas, E., Tolnay, P., Szell, E., and Bagdy, D. (1978). Inhibition of thrombin and trypsin by tripeptide aldehydes. Int. J. Pept. Protein Res. 12, 217-221.
4. Bajusz, S., Szell, E., Bagdy, D., Barbas, E., Horvath, G., Dioszegi, M., Fittler, Z., Szabo, G., Juhasz, A., Tomori, E., and Szilagyi, G. (1990). Highly active and selective anticoagulants. D-Phe-ProArg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative D-Me-Phe-Pro-Arg-H. J. Med. Chem. 33, 1729-1735.
5. Balasubramanian, N., Laurent, D.R.St., Federici, M.E., Meanwell, N.A., Wright, J.J., Schumacher, W.A., and Seiler, S.M. (1993). Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series. J. Med. Chem. 36, 300-303.
6. Banner, D.W., and Hadvary, P. (1991). Crystallographic analysis at 3.0 Å resolution of the binding to human thrombin of four active site-directed inhibitors. J. Biol. Chem. 266, 20085-20093.
7. Bar-Shavit, R., Kahn, A., Wilner, G.D., and Fenton, J.W.II. (1993) Monocyte chemotaxis stimulation by a specific exosite region in thrombin. Science 220, 728-731.
8. Bar-Shavit, R., Kahn, A., Wilner, G.D., Mann, K.G., and Fenton, J.W.II. (1984). Localization of a chemiotactic domain in human thrombin. Biochemistry 23, 397-400.
9. Bar-Shavit, R., Kahn, A., Mann, K.G., and Wilner, G.D. (1986). Growth-promoting effects of esterolytically inactive thrombin on macrophages. Cell. Biochem. 32, 261-272.
10. Betz, A., Hopkins, P.C.R., le Bonniec, B.F., and Stone, S.R. (1994). Contribution of interactions with the core domain of hirudin to the stability of its complex with thrombin. Biochem. J. 298, 507-510.
11. Bizios, R., Lai, L., Fenton, J.W.II, and Malik, A.B. (1986). Thrombin-induced chemotaxis and aggregation of neutrophilis. J. Cell. Physiol. 128, 485-490.
12. Bode, W., and Huber, R. (1992). Natural protein proteincase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204, 443-452.
13. Bode, W., Mayr, I., Baumann, U., Huber, R., Stone, S.R., and Hofsteenge, J. (1989). The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg-chloromethylketone and significance of theTyr-Pro-Pro-Trp insertion segment. EMBO J. 8, 3467-3475.
14. Bode, W., Turk, D., and Karshikov, A. (1992a). The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: structure analysis overall structure electrostatic properties detailed active-site geometry and structure-function relationships. Protein Sci. 1, 426-471.
15. Bode, W., Huber, R., Rydel, T. J., and Tulinsky, A. (1992b). X-ray crystal structures of human α-thrombin and of human thrombini-hirudin complex. In: Thrombin Structure and Function. L.J. Berliner, ed. (New York: Plenum Press), pp. 3-61.
16. Bouton, M.C., Jandrot-Perrus, M., Bezeaud, A., and Guillin, M.C. (1993). Late fibrin(ogen) fragment E modulates human α-thrombin specificity. Eur. J. Biochem. 215, 143-149.
17. Brandstetter, H., Turk, D., Hoeffken, H.W., Grosse, D., Stürzebecher, J., Martin, P.D., Ewards, B.F.P., and Bode, W. (1992). Defined 2.3 Å x-ray crystal structure of bovine thrombin complexes formed with the benzamldine and arginine-based thrombin Inhibitors NAPAP 4-TAPAP and MQPA. J. Mol. Biol. 226, 1085-1099.
18. Cacciolla, J., Fevig, J.M., Alexander, R.S., Brittelli, D.R., Kettner, C.A., Knabb, R.M., and Weber, P.C. (1996). Synthesis of conformationally-restricted boropeptide thrombin inhibitors. Bioog. Med. Che. Lett. 6, 301-306.
19. Chen, L.B., and Buchanam, J.M. (1975). Mitogenic activity of blood components, I. Thrombin and prothrombin. Proc. Natl. Acad. Sci. USA. 72, 131-135.
20. Chirgadze, N.Y., Sall, D. J., Klimkowski, V.J., Clawson, D.K., Briggs, S.L., Hermann, R., Smith, G.F., Gifford-Moore, D.S., and Wery, G.P. (1997). The crystal structure of human α-thrombin complexed with LY178550, a nonpeptidyl, active site-directed, inhibitor. Protein Sci. 6, 1412-1417.
21. tthrombin. Identification of lysyl residues in α-thrombin that are critical for heparin and fibrin(ogen) interactions. J. Biol. Chem. 264, 18419-18425.
22. Costanzo, M.J., Maryanoff, B.E., Hecker, L.R., Schott, M.R., Yabut, S.C., et al. (1996). Potent thrombin inhibitors that probe the S1′ subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group. J. Med. Chem., 39, 3039-3043.
23. Cunningham, D.D., and Farrell, D.H. (1986). Thrombin interactions with cultured fibroblasts: relationship to mitogenic stimulation. Ann. NY Acad. Sci. USA 485, 240-248.
24. Davie, E.W., Fujikawa, K., and Kisiel, W. (1991). The coagulation cascade: initiation, maintenance and regulation. Biochemistry 30, 10364-10370.
25. De Simone, G., Balliano, G., Milla, P., Gallina, C., Giordano, C., Tarricone, C., Rizzi, M., Bolognesi, M., and Ascenzi, P. (1997). Human α-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-α-azaLys p-nitrophenyl ester: A kinetic, thermodinamic and X-ray crystallographic study. J. Mol. Biol. 269, 558-569.
26. De Simone, G., Lombardi, A., Galdiero, S., Nastri, F., Della Morte, R., Staiano, N., Pedone, C., Bolognesi, M., and Pavone, V. (1998). Hirunorms are true hirudin mimetics: the crystal structure of human α-thrombin:hirunorm V complex. Protein Sci. 7, 243-253.
27. Di Cera, E., Dand, Q.D., and Ayala, Y.M. (1997). Molecular mechanism of thrombin function. Cell. Mol. Life Sci. 53, 701-730.
28. DiMaio, J., Gibb, B., Munn, D., Lefebre, J., Ni, F., and Konishi, Y. (1991). A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. FEBS Letters 282, 47-52.
29. DiMaio, J., Gibb, B., Lefebre, J., Konishi, Y., Munn, D., and Yue, S.Y. (1992). Synthesis of a homogeneous series of ketomethylene arginyl pseudopeptides and application to low molecular weight hirudin-like thrombin inhibitors. J. Med. Chem. 35, 3331-3341.
30. Feng, D.-M., Gardell, S.J., Lewis, S.D., Bock, M.G., Chen, Z., et al. (1997). Discovery of a novel, selective and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. J. Med. Chem. 40, 3726-3733.
31. Fenton, J.W. (1988). Thrombin specificity. Ann. NY Acad. Sci. 370, 468-495.
32. Fenton, J.W.II, and Bing, D.H. (1986). Thrombin active-site regions. Semin. Thromb. Haemostasis 12, 200-208.
33. Fenton, J.W.II, Olson, TA, Zabinski, M.P., and Wilner, G.D. (1988). Anion binding exosite of human α-thrombin and fibrin(ogen) recognition. Biochemistry 27, 7106-7112.
34. Fenton, J.W.II, Ofosu, F.A., Moon, D.G., and Maraganore, J.M. (1991). Thrombin structure and function: Why thrombin is the primary target for antithrombotics. Blood Coag: Fibrinol. 2, 69-75.
35. F́thière, J., Tsuda, Y, Coulombe, R., Konishi, Y., and Cygler, M. (1996). Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human α-thrombin. Protein Sci. 5, 1174-1183.
36. Fevig, J.M., Abelman, M.M., Brittelli, D.R., Kettner, C.A., Knabb, R.M., and Weber, P.C. (1996). Design and synthesis of ring-costrained boropeptide thrombin inhibitors. Bioorg. Med. Che. Lett. 6, 295-300.
37. Fusetani, N., Matsunaga, S., Matsumoto, H., and Takebayashi,Y. (1990). Cyclotheonamides, potent thrombin inhibitors, from a marine sponge Theonella sp. J. Am. Chem. Soc. 112, 7053-7054.
38. Gan, Z.-R., Li, Y., Chen, Z., Lewis, S.D., and Shafer, JA (1994). Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivatlon by antithrombin III. J. Biol. Chem. 269, 1301-1305.
39. Ganesh, V., Lee, A.Y., Clardy, J., and Tulinsky, A. (1996). Comparison of the structures of cyclotheonamide A complexes of human α-thrombin arid bovine β-trypsih. Protein Sci. 5, 825-835.
40. Gast, A., and Tschopp, T.B. (1995). Inhibition of extrinsic and in thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coag. Fibrinol. 6, 533-560.
41. Gronke, R.S., Bergman, B.L., and Baker, J.B. (1987). Thrombin interaction with platelets. Influence of a platelet protease nexin. J. Biol. Chem. 262, 3030-3036.
42. Grütter, M.G., Priestle, J.P., Rahuel, J., Grossenbacher, H., Bode, W., Hofsteenge, J., and Stone, S.R. (1990). Crystal Structure of the thrombin-hirudin complex: a novel mode of serine proteinase inhibition. EMBO J. 9, 2361-2365.
43. Guillin, M.-C., Bezeaud, A., Bouton, M.-C., and Jandrot-Perrus, M. (1995). Thrombin specificity. Thromb. and Hemost. 74, 129-133.
44. Haghihara, M., and Schreiber, S.L. (1992). Reassignment of stereochemistry and total synthesis of the thrombih inhibitor cyclotheonamide B. J. Am. Chem. Soc. 114, 6570-6571.
45. Håkansson, K., Tulinsky, A., Abelman, M.M., Miller, T.A., Vlasuk, G.P., Bergum, P.W., Lim-Wilby, M.S.L., and Brunck, T.K. (1995). Crystallographic structure of a peptidyl keto acid inhibitor and human α-thrombin. Bioorg. Med. Chem. Lett. 3, 1009-1017.
46. Hoffsteenge, J., and Stone, S.R. (1987). The effect of thrombomodulin on the cleavage of fibrinogen fragments by thrombin. Eur. J. Biochem. 168, 49-56.
47. Hopfner, K.P., and Di Cera, E. (1992). Energetics of thrombin-fibrinogen interaction. Biochemistry 31, 11567-11571.
48. Hortin, G.L., and Trimpe, B.L (1991). Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates. J. Biol. Chem. 266, 6866-6871.
49. Ishihara, H., Connolly, A. J., Zeng, D., Kahn, M. L., Zheng, Y.W., Timmons, C., Tram, T., and Coughlin, S.R. (1997). Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386, 502-505.
50. Iwanowicz, E. J., Lau, W.F., Lin, J., Roberts, D.G.M., and Seiler, S.M. (1994). Retro-binding tripeptide thrombin active-site inhibitors: discovery synthesis and molecular modeling. J. Med. Chem. 37, 2122-2124.
51. Jakubowski, J.A., and Maraganore, J.M. (1990). Inhibition of coagulation and thrombin induced platelet activities by a synthetic dodecapeptide modeled on the carboxy terminus of hirudin. Blood 75, 399-406.
52. 2Cl: A selective label for thrombin. Thromb. Res. 14, 969-973.
53. Kettner, C., Mersinger, L., and Knabb, R. (1990). The selective inhibition of thrombin by peptides boroarginine. J. Biol. Chem. 265, 18289-18297.
54. Kikumoto, R., Tamao, Y., Ohkubo, K., Tezuka, T., Tonomura, S., Okamoto, S., Funahara, Y., and Hijikata, A. (1980). Thrombin inhibitors. 2. Derivatives of Nα-substituted-L-arginine. J. Med. Chem. 23, 830-836.
55. Kikumoto, R., Tamao, Y., Ohkubo, K., Tezuka, T., Tonomura, S., Okamoto, S., and Hijikata, A. (1980). Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of Nα-substituted-L-arginine. J. Med. Chem. 23, 1293-1299.
56. Kikumoto, R., Tamao, Y., Tezuka, T., Tonomura, S., Hara, N., Ninomiya, K., Hijikata, A., and Okamoto, S. (1984). Selective inhibition of thrombln by 2R,4R-4-methyl-1-N2-[3-methyl-1,2,3,4-tetrahydro-8-quinolinylsulphonyl-L- arginyl]-2-piperidine-carboxylic. Biochemistry 23, 85-89.
57. Kimball, S.D. (1995). Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul. Fibrinol. 6, 511-519.
58. Kline, T., Hammond, C., Bourdon, P., and Maraganore, J. (1991). Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem. Biophys. Res. Commun. 177, 1049-1055.
59. Krishnan, R., Tulinsky, A., Vlasuk, G.P., Pearson, D., Vallar, P., Bergum, P., Brynck, T.K., and Ripka, W.C. (1996). Synthesis structure and structure-activity relationships of divalent thrombin inhibitors containing an, α-keto-amide transition state mimetic. Protein Sci 5, 422-433.
60. α-acetyl-hirudin 45-65. FEBS Letters 211, 10-16.
61. Krstenansky, J.L., and Mao, S.J.T. (1991). Structure function relationships of the C-terminal functional domain of hirudine and its variants. Blood Coag. Fibrinolysis 2, 91-96.
62. Krstenansky, J.L. Owen, T.J. Yates, M.T., and Mao, S.J.T. (1987). Anticoagulant peptides: nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site of thrombin. J. Med. Chem. 30, 1688-1691.
63. Krstenansky, J.L., Owen, T.J., Yates, M.T., and Mao, S.J.T. (1988). Design synthesis and antithrombin activity for conformationally restricted analogs of peptide anticoagulants based on the C-terminal region of the leech peptide hirudin. Biochim. et. Biophys. Acta 957, 53-59.
64. Krstenansky, J.L, Owen, T.J., Yates, M.T., and Mao, S.J.T. (1990a). The C-terminal binding domain of hirullin P18: antithrombic activity and comparison to hirudin peptides. FEBS Letters 269, 425-429.
65. Krstenansky, J.L., Broersma, R.J., Owen, T.J., Payne, M.H., Yates, M.T, and Mao, S.J.T. (1990b). Development of MDL 28050 a small antithrombin agent based on a functional domain of the leech protein hirudin. Thromb. Haemostasis 63, 208-214.
66. Laskowski, M., and Kato, I. (1980). Protein inhibitors of proteinases. Ann. Rew. Biochem. 49, 593-626.
67. Lesk, A. M., and Fordham, W. D. (1996). Conservation and Variability in the structures of serine proteinases of the chymotrypsin family. J. Mol. Biol. 258, 501-537.
68. Lewis, S.D., Ng, A.S., Baldwin, J.J., Fusetani, N., Naylor, A.M., and Shafer, J.A. (1993). Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A, Tromb. Res. 70, 173-190.
69. Lombardi, A., Nastri, F., Della Morte, R., Rossi, A., De Rosa, A., Staiano, N., Pedone, C., and Pavone, V. (1996). Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed α-thrombin inhibitors. J. Med. Chem. 39, 2008-2017.
70. Lyle, T.A., Chen, Z., Appleby, S.D., Freidinger, R.M., Gardens, S.J., et al. (1997). Synthesis, evaluation, and crystallographic analysis of L-371,912: a potent and selective active-site thrombin inhibitor. Biorg. Med. Chem. Lett. 7, 67-72.
71. Malley, M.F., Tabernero, L., Chang, C.Y., Ohringer, S.L., Roberts, D.G.M., Das, J., and Sack, J.S. (1996). Crystallographic determination of the structures of human α-thrombin complexed with BMS-186282 and BMS-189090. Protein Sci. 5, 221-228.
72. Maraganore, J.M., Bourdon, P., Jablonski, J., Ramachandran, K.L., and Fenton, J.W.II. (1990). Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095-7101.
73. Markwardt, F. (1994). The development of hirudin as.an antithrombotic drug. Thrombosis Res. 74, 1-23.
74. Martin, P.D., Robertson, W. Turk, D., Huber, R., Bode, W., and Edwards, B.F.B. (1992). The structure of residues 7-16 of the Aα chain of human fibrinogen bound to bovine thrombin at 2.3Å resolution. J. Biol, Chem. 267, 7911-7920.
75. Martin, P.D., Malkowski, M.G., DiMalo, J., Konishi, Y., Ni, F., and Edwards, B.F.B. (1996). Bovine thrombin complexed with an uncleavable analog of residues 7-19 of fibrinogen Aa: geometry of the catalytic triad and interactions of the P1′, P2′, and p3′ substrate residues. Biochemistry 35, 13030-13039.
76. Maryanoff, B.E., Qiu, X., Padmanabhan, K.P, Tulinsky, A., Almond, H.R. Jr., et al. (1993). Moleoular basis for the inhibition of human α-thrombin by the macrocyclic peptide cyclotheonamide A. Proc. Natl. Acad. Sci. 90, 8048-8052.
77. Mathew, I.I., Padmanabhan, K-P., Ganesh, V., Tulinsky, A., Isshii, M., Chen, J., Tfek, C.W., and Coughlin, S.R. (1994a). Crystal lographic structures of thrombin complexed with thrombin receptor of peptides: existence of expected and novel binding modes. Biochemistry 33, 3266-3279.
78. Mathews, I.I., Padmanabhan, K.P., Tulinsky, A., and Saddler, J.E. (1994b). Structures of a nonadecapeptide of the fifth EGF domain of thrombomodulin complexed with thrombin. Biochemistry 33, 13547-13552.
79. Matthews, J.H., Krishnan, R., Costanzo, M.J., Maryanoff, B.E., and Tulinsky, A. (1996). Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1′ binding site. Biophys. J. 71, 2830-2839.
80. Muramatsu, R., Komatsu, Y., Nukui, E., Okayama, T., Morikawa, T., Kobashi, K., and Hayashi, H. (1996). Structure-activity studies on C-terminal hirudin peptides containing sulfated tyrosine resides. Int. J. Pep. Protein Res. 48, 167-173.
81. α-NN-dimethyl-carbamoyl-α-azalysine p-nitrophenyl ester: a comparative kinetic and x-ray crystallographic study. J. Mol. Biol. 258, 851-859.
82. Naski, M-C., Fenton, J.W., Maraganore, J.M., Olson, S.T., and Shafer, J.A. (1990). The COOH-terminal domain of hirudin. An exosite-dlrected competitive inhibitor of the action of α-thrombine on fibrinogen. J. Biol. Chem. 265, 13484-13489.
83. Ni, F., Ripoll, D.R., Martin, P.D., and Edwards, B.F.P. (1992). Solution structure of a platelet receptor peptide bound to bovine α-thrombin. Biochemistry 31, 11551-11557.
84. Nienaber, V.L., and Amparo, E.C. (1996). A noncleavable retro-binding peptide that spans the substrate binding cleft of serine proteases. Atomic structure of nazumamide A: human thrombin. J. A. Chem. Soc. 118, 6807-6810.
85. Nienaber, V.L., Mersinger, L.J., and Kettner, C.A. (1996). Structure-based understanding of ligand affinity using human thrombin as a model system. Biochemistry 35, 9690-9699.
86. Noeske-Jungblut, C., Haendler, B., Donner, P., Alagon, A., Possani, L., and Schleuning, W.-D. (1995). Triabin, a highly potent excite thrombin inhibitor. J. Biol. Chem. 270, 28629-28634.
87. Obst, U., Gramlich, V., Diederich, F., Weber, L., and Banner, D.W. (1995). Design of novel, nonpeptidic thrombin inhibitors and stature of a thrombin-inhibitor complex. Angew. Chem. Int. Ed. Engl. 34, 1739-1742.
88. Obst, U., Banner, D.W., Gramlich, V., Weber, L., and Diederich, F. (1997). Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-hinhtbitor complexes. Chem. and Biol. 4, 287-295.
89. Okamoto, S., Kinjo, K., Hijikata, A., Kikumoto, R., Tamao, Y., Ohkubo, K., and Tonomura, S. (1980). Thrombin inhibitors. 1. Ester derivatives of Nα-(arylsulfonyl)-L-arginine. J. Med. Chem. 23, 827-830.
90. Okamoto, S., Hijikata, A., Kikumoto, R., Tonomura, S., Hara, N., Ninomiya, K., Maruyama, A., Sugano, M., and, Y. (1981). Potent Inhibition of thrombin by the newly synthesized arginine derivative No 805. The importance of stereostructure of its carboxamide portion. Biochem. Bibphys: Res. Commun. 101, 440-446.
91. Okayama, T., Muramatsu, R., Seki, S., Nukui, E., Hagiwara, M., Hayashi, H., and Morikawa, T. (1996). Anticoagulant peptides. synthesis, stability and antithrombin activity of hirudin-C-terminal related peptides and their disulfated analog. Chem. Pharm. Bull. 44, 1344-1350.
92. Olson, S.T., and Björk, I. (1992). Regulation of thrombin by antithrombin and heparin cofactor II. In: Thrombin Structure and Function. L. J. Berliner, ed. (New York: Plenum Press), pp. 159-217.
93. Owen, T.J., Krstenansky, J.L., Yates, M.T., and Mao, S.J.T. (1988). N-terminal requirements of small peptide anticoagulants based on hirudin54-65. J. Med. Chem. 37, 1009-1011.
94. Powers, J.C., and Kam, C.-M. (1992). Synthetic substrates and Inhibitors of thrombin. In: Thrombin Structure and Function. L. J. Berliner, ed. (New York: Plenum Press), pp. 117-158.
95. Priestle, J.P., Rahuel, J., Rink, H., Tones, M., and Grütter, M.G. (1993). Changes in interaction in complexes of hirudin derivatives and human α-thrombin due to different crystal forms. Protein Sci. 2, 1630-1642.
96. Qiu, X., Padmanabhan, K.P., Carperos, V.E., Tulinsky, A., Kline, T., Maraganore, J.M., and Fenton, J.W.II. (1992). Structures of hirulog 3-thrombin complex and nature of S′ subsites of substrates and inhibitors. Biochemistry 31, 11689-11697.
97. Qiu, X., Yin, M., Padmanabhan, K.P., Krstenansky, J.L, and Tulinsky, A. (1993). Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. J. Biol. Chem. 268, 20318-20326.
98. Rehse, P.H., Steinmetzer, T., Li, Y., Konishi, Y., and Cygler, M. (1995). Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin. Biochemistry 34, 11537-11544.
99. Rogers, S.J., Pratt, C.W., Whinna, H.C., and Church, F.C. (1992). Role of thrombin exosite in inhibition by heparin cofactor II. J. Biol. Chem. 267, 3613-3617.
100. Rosenberg, R. D., and Damus, P. S. (1973). The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 248, 6490-6505.
101. Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C., and Fenton, J.W.II (1990). The structure of a complex of recombinant hirudin and human α-thrombin. Science 249, 277-280.
102. Rydel, T.J., Tulinsky, A., Bode, W., and Huber, R. (1991). Refined structure of the hirudin-thrombin complex. J. Mol. Biol. 221, 583-601.
103. Sawyer, R.T. (1986). Leech Biology and Behaviour, Vol.2 (London: Clarendon, Oxford University Press).
104. Schlechter, I., and Berger, A. (1967). On the size of the active site in proteinases l Papain. Biochem. Biophys. Res. Commun. 27, 157-162.
105. Semple, J.E., Rowley, D.C., Brunck, T.K., Ha-Uong, T., Minami, N.K., et al. (1996). Design, synthesis and evolution of a novel, selective, and orally bioavalable class of thrombin inhibitors: P1-arginyl derivatives incorporating P3-P4 lactam sulfonamide moieties. J. Med. Chem. 39, 4531-4536.
106. Sheehan, J.P., and Sadler, J.E. (1994). Molecular mapping of the heparin binding exosite. of thrombin. Proc. Natl. Acad. Sci. USA 91, 5518-5522.
107. Shuman, R.T., Rothenberger, R.B., Campbell, C.S., Smith, G.F., Gifford-Moore, D.S., and Gesellchen, P.D. (1993). Highly selective tripeptide thrombin inhibitors. J. Med. Chem. 36, 314-319.
108. Skrzypczak-Jankun, E., Carperos, V.E., Ravichandran, K.G., Tulinsky, A., Westbrook, M., and Maraganore, J.M. (1991). Structure of hirugen and hirulog 1 complexes of α-thrombin. J. Mol. Biol. 221, 1379-1393.
109. Slon-Usakiewicz, J.J., Purisima, E., Tsuda, Y., Sulea, T., Pedyczak, A., Féthière, J., Cygler, M., and Konishi, Y. (1997). Nonpolar interactions of thrombin S′ subsites with its bivalent inhibitor: methyl scan of the inhibitor linker. Biochemistry 36, 13494-13502.
110. Srinivasan, J., Hu, S., Hrabal, R., Zhu, Y., Komives, E.A.,and Ni, F. (1994). Thrombin bound structure of an EGF subdomain from Human thrombomodulin determined by transferred nuclear Ovherauser effects. Biochemistry 33, 3553-3560.
111. Steiner, V., Knecht, R., Borsen, K.O., Gassmann, E., Stone, S.R., Raschdorf, F., Schlaeppi, J.-M., and Maschler, R. (1992). Primary structure and function of novel O-glycosylated hirudins from the leech Hirudinaria manillensis. Biochemistry 31, 2294-2298.
112. Stone, S.R., and Hofsteenge, J. (1986). Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25, 4622-4628.
113. Stone, S.R., and Maraganore, J.M. (1992). Hirudin interactions with thrombin. In: Thrombin Structure and Function. L. J. Berliner, ed. (New York: Plenum Press), pp.219-256.
114. Stubbs, M.T., and Bode, W. (1993). A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69, 1-58.
115. Stubbs, M.T., and Bode, W. (1995). Structure and specificity in coagulation and its inhibition. Trends Cardiovasc. Med. 5, 157-166.
116. Stubbs, M.T, Oschkinat, H., Mayr, I., Huber, R., Angliker, H., Stone, S.R., and Bode, W. (1992). The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur. J. Biochem. 206, 187-195.
117. Stürzebecher, J., Markwardt, F., Voigt, B., Wagner, G., and Walsmann, P. (1983). Cyclic amides of Na-arylsulfonylamino acylated 4-amidinophenylalanine - tight binding of thrombin. Thromb. Res. 29, 635-642.
118. Stürzebecher, J., Markwardt, F., Voigt, B., and Wagner, G. (1984). Inhibition of bovine and human thrombins by derivatives of benzamidines. Thromb. Res. 36, 457-467.
119. Suzuki, K, Nishioka, J., and Hayashi, T. (1990). Localization of thrombomodulin-binding site within human thrombin. J. Biol. Chem. 265, 13263-13267.
120. Szewczuk, Z., Gibbs, B.F., Yue, S.Y., Purisima, E.O., and Konishi, Y. (1992). Conformationaily restricted thrombin inhibitors resistant to proteolytic digestion. Biochemistry 31, 9132-9140.
121. Szewczuk, Z., Gibbs, B.F., Yue, S.Y., Purisima, E.O., Zdanov, A., Cygler, M., and Konishi, Y. (1993). Design of a linker for trivalent thrombin inhibitors: interaction of the main chain of the linker with thrombin. Biochemistry 32, 3396-3404.
122. Tabernero, L., Chang, C.Y., Ohringer, S.L., Lau, W.F., Iwanowicz, E.J., Han, W., Wang, T.C., Seiler, S.M., Roberts, D.G.M., and Sack, J.S. (1995). Structure of a retro-binding peptide inhibitor complexed with human α-thrombin. J. Mol. Biol. 246, 14-20.
123. Tapparelli, C., Metternich, R., Ehrhardt, C., and Cook, N. S. (1993). Synthetic low molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol. Sci. 74, 366-376.
124. α-guanidiniobenzoyl derivatives of hirudin 54-65 containing stabilized carboxyl or phosphoryl groups on the side chain of phenylalanine-63. J. Med. Chem. 37, 625-629.
125. Tollefsen, D.M., Feagler, J.R., and Majerus, P.W. (1974). The binding of thrombin to the surface of human platelets. J. Biol. Chem. 249, 2646-2651.
126. Tollefsen, D.M., Majerus, D.W., and Blank, M.K. (1982). Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257, 2162-2169.
127. Tsuda, Y., Cygler, M., Gibbs, B.F., Pedyczac, A., Féthière, J., Yue, S.Y., and Konishi, Y. (1994). Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of non-substrate-type active site inhibitors. Biochemistry 33, 14443-14451.
128. Tucker, T.J., Lumma, W.J., Mulichak, A.M., Chen, Z., Naylor-Olsen, A.M., Lewis, S.D., Lucas, R., Freidinger, R.M., and Kuo, L.C. (1997a). Design of highly potent noncovalent thrornbin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J. Med. Chem. 40, 830-832.
129. Jucker, T.J., Lumma, W.J., Lewis, S.D., Gardell, S.J., Lucas, B.J., Baskin, E.P., Woltmann, R., Lynch, J.J., Lyle, E.A., Appleby, S.D., Chen, I.-W., Dancheck, K.B., and Vacca, J.P. (1997b). Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. J. Med. Chem. 40, 1565-1569.
130. Tulinsky, A., and Qiu, X. (1993). Active site and exosite binding of α-thrombin. Blood Coagul. Fibrinol. 4, 305-312.
131. van de Locht, A., Lamba, D., Bauer, M., Huber, R., Friedrich, T., Kröger, B., Höffken,W., and Bode, W. (1995). Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J. 14, 5149-5157.
132. van de Locht, A., Stubbs, M.T., Bode, W., Friedrich, T., Bollschweiler, C., Höffken, W., and Huber, R. (1996). The ornithodorin-thrombin crystal structure a key to the TAP enigma? EMBO J. 15, 6011-6017.
133. Vitali, J., Martin, P.D., Malkowski, M.D., Robertson, W.D., Lazar, J.B., Winant, R.C., Johnson, P.J., and Edwards, B.F.P. (1992). The stucture of a complex of bovine α-thrombin and recombinant hirudin at 2.8 A resolution. J. Biol. Chem. 267, 17670-17678.
134. Vu, T.K.H., Wheaton, V.I., Hung, D.T., Charo, I., and Coughlin, S.R. (1991a). Domains specifying thrombin receptor interaction. Nature 353, 674-677.
135. Vu, T.K.H., Hung, D.T., Wheaton, V.I., and Coughlin, S.R. (1991b). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057-1068.
136. Wallis, R.B. (1988). Hirudins and the role of thrombin: lessons from leaches. Trends Pharm. Sci. 9, 425-427.
137. Walsmann, P., and Markwardt, F. (1981). Biochemische and pharmakologische Aspekte des Thrombininhibitors Hirudin. Pharmazie 36, 653-660.
138. Walsmann, P. (1988). Über den Einsatz des spezifischen Thrombininhibitors Hirudin für diagnostische and biochemische Untersuchungen. Pharmazie 43, 737-744.
139. Weber, P.C., Lee, S.-L., Lewandowski, F.A., Schadt, M.C., Chang, C.-H., and Kettner, C.A. (1995). Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArgOH and its lysine, amidine, homolysine and ornitine analogs. Biochemistry 34, 3750-3757.
140. Zdanov, A., Wu, S., DiMaio, J., Konishi, Y., Li, Y., Wu, X., Edwards, B.F.P., Martin, P.D., and Cygler, M. (1993). Crystal structure of the complex of human α-thrombin and nonhydrolyzable bifunctional inhibitors hirutonin-2 and hirutonin-6. Proteins: Struc. Funct. Genet. 17, 252-265.